PMID- 20038314
OWN - NLM
STAT- MEDLINE
DCOM- 20111205
LR  - 20220321
IS  - 1000-467X (Print)
IS  - 1944-446X (Linking)
VI  - 29
IP  - 1
DP  - 2010 Jan
TI  - [Relationship between HER2/neu gene amplification and protein expression and 
      prognosis in patients with advanced gastric carcinoma].
PG  - 76-81
AB  - BACKGROUND AND OBJECTIVE: There is a mounting evidence of the role of HER2 
      overexpression inpatients with gastric cancer, and it has been solidly correlated 
      with poor outcomes and more aggressive diseases. This study was to investigate 
      the relationship between the expression of HER2/neu and the clinical 
      characteristics of advanced gastric carcinomas, including survival. METHODS: The 
      clinical data of 83 patients admitted in Cancer Hospital, Chinese Academy of 
      Science, from 2006 to 2008 were reviewed. The HER2/neu status in 83 advanced 
      gastric carcinomas was evaluated using immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH). The survival rate was calculated by 
      Kaplan-Meier method and the log-rank test using SPSS13.0 software. RESULTS: The 
      median age of the patients was 60 years and the male-to-female ratio was 2.95:1. 
      HER2/neu overexpression (2+ and 3+) and amplification were found in 25 (30.1%) 
      and 29 (34.9%) advanced gastric carcinomas, respectively. HER2/neu 
      amplification/overexpression was associated with worse survival in patients with 
      advanced gastric carcinoma. The median survival of the patients without HER2/neu 
      amplification was 12.6 months and that of those with HER2 amplification was 5.5 
      months. CONCLUSIONS: HER2/neu status may be a clinical predictor of prognosis in 
      advanced gastric cancer patients.
FAU - Song, Yan
AU  - Song Y
AD  - Department of Medical Oncology, Cancer Hospital, Peking Union Medical College, 
      Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
FAU - Huang, Jing
AU  - Huang J
FAU - Wang, Jin-Wan
AU  - Wang JW
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - England
TA  - Chin J Cancer
JT  - Chinese journal of cancer
JID - 101498232
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Adenocarcinoma/drug therapy/genetics/metabolism/pathology/secondary
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma, Signet Ring Cell/drug therapy/genetics/metabolism/pathology/secondary
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - *Genes, erbB-2
MH  - Humans
MH  - Liver Neoplasms/secondary
MH  - Lung Neoplasms/secondary
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Receptor, ErbB-2/*metabolism
MH  - *Stomach Neoplasms/drug therapy/genetics/metabolism/pathology
MH  - Survival Rate
EDAT- 2009/12/30 06:00
MHDA- 2011/12/13 00:00
CRDT- 2009/12/30 06:00
PHST- 2009/12/30 06:00 [entrez]
PHST- 2009/12/30 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 1000-467X20100164 [pii]
AID - 10.5732/cjc.009.10377 [doi]
PST - ppublish
SO  - Chin J Cancer. 2010 Jan;29(1):76-81. doi: 10.5732/cjc.009.10377.